Engineered therapeutic proteimer compositions and related methods

WO2026096827A3PCT designated stage Publication Date: 2026-06-04CROSSLIFE TECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
CROSSLIFE TECHNOLOGIES INC
Filing Date
2025-10-30
Publication Date
2026-06-04

AI Technical Summary

Technical Problem

Existing biotherapeutic technologies, particularly antibody therapeutics, are costly to manufacture and the drug discovery process is laborious, necessitating improved methods for generating novel biopharmaceuticals with high specificity and affinity.

Method used

Development of engineered Proteimer compositions, specifically non-native variants of protein scaffolds like TEX-S2/S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2, through rational mutagenesis and phage display, to create high-affinity binders for diverse targets including proteins, nucleic acids, and small molecules, enhancing biopharmaceutical applications.

Benefits of technology

The Proteimers achieve specificity and affinity comparable to antibodies, enabling broad therapeutic applications, including treatment of diseases like cancer, Alzheimer's, Parkinson's, and COVID-19, and reducing toxicity of chemotherapeutics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025053423_04062026_PF_FP_ABST
    Figure US2025053423_04062026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.
Need to check novelty before this filing date? Find Prior Art